Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

Leukemia

Volumn 29, Issue 8, 2015, Pages 1702-1712

  Li, L ^a   Pongtornpipat, P ^a   Tiutan, T ^a   Kendrick, S L ^a   Park, S ^a   Persky, D O ^a   Rimsza, L M ^a   Puvvada, S D ^a   Schatz, J H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 9; CYTARABINE; DINACICLIB; DOXORUBICIN; ETOPOSIDE; PROTEIN BCL 2; PROTEIN MCL 1; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; MESSENGER RNA; PYRIDINIUM DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TISSUE MICROARRAY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, INBRED NOD; MICE, SCID; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINIUM COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938953633     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.99     Document Type: Article

References (50)

1. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large b-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
4. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011: 498-505.
5. Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R (X)CHOP era. Ann Oncol 2014; 25: 2124-2133.
6. George A, Tam CS, Seymour JF. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone? Leuk Lymphoma 2013; 54: 2575-2576.
7. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive cd20+ b-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-2380.
8. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS et al. Immunohis-tochemical double-hit score is a strong predictor of outcome in patients with diffuse large b-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-3467.
9. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al. Concurrent expression of MYC and BCL2 in diffuse large b-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3452-3459.
10. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021-4031, quiz 4250.
11. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large b cell lymphoma. Cancer Cell 2012; 22: 359-372.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
13. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012; 30: 3127-3135.
14. Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121: 2253-2263.
15. Wenzel S-S, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 2013; 27: 1381-1390.
16. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-2353.
17. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98: 8012-8017.
18. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-110.
19. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 2011; 147: 554-564.
20. Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J Exp Med 2014; 211: 1379-1391.
21. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208: 1799-1807.
22. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-2978.
23. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA poly-merase II transcription in vivo. J Biol Chem 2001; 276: 31793-31799.
24. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65: 5399-5407.
25. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8: 3527-3538.
26. Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic. Leukemia 2015; 29: 1524-1529.
27. Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad A-S et al. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One 2014; 9: e108371.
28. Schuller A, Booher R, Cadzow L, Angagaw M, Harmonay L, Qu X et al. Abstract 699: optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models. Cancer Res 2013; 73: 699-699.
29. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185.
30. Ertel F, Nguyen M, Roulston A, Shore GC. Programming cancer cells for high expression levels of Mcl1. EMBO Rep 2013; 14: 328-336.
31. Mills JR, Hippo Y, Robert F, Chen SMH, Malina A, Lin C-J et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853-10858.
32. Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM et al. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 2014; 45: 2144-2153.
33. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
34. Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 2008; 4: 357-365.
35. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lym-phocytic leukemia. Blood 2009; 113: 4637-4645.
36. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723-732.
37. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014; 166: 891-901.
38. Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004; 103: 2276-2283.
39. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
40. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58-70.
41. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012; 21: 547-562.
42. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
43. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A et al. Ritux-imab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
44. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
45. Van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
46. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67: 782-791.
47. Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou Y-M et al. A first-inhuman, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013; 11: 259.
48. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011; 25: 1444-1451.
49. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 2014; 32: 5s.
50. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285-2288.